Effectiveness of Medtronic Intrathecal Drug Delivery Pump Personal Therapy Manager in Spasticity Management

Friday, May 29, 2015
Griffin Hall
Lukmon Babajide, Medical Student , Physical Medicine and Rehabilitation, UT Southwestern Medical Center, Dallas, TX


Intrathecal drug delivery pumps are used as in interventional device for spasticity managementfor patients with neurological disorders. The purpose of this research is to determine efficiency and patient satisfaction with the myPTM device that has been used successfully for pain management. The outcomes from this study could lead to improved efficiency of spasticitymanagement by physician and patient. The benefits of patient controlled management of spasticity through the myPTM device are numerous. It could reduce pain, improve range of motion, positioning, and function, as well as lead to a sense of greater patient involvement in care. Further, observation of the utilization of the pump may aid in physician controlled dosing that provides better relief for the patient while maintaining adequate muscle function.


It is hypothesized that the institution of the myPTM pump will reduce periodic spasticity and increase patient satisfaction. A retrograde study was conducted in order to reveal efficacy of the myPTM pump in select patients. The study includes patients who used myPTM for spasticity or pain between January 01, 2013 and April 15, 2014.


Charts were reviewed from the electronic medical record (UTSW EPIC) for patients utilizing the myPTM during the time mentioned and then statistically analyzed for any trends that elucidated satisfaction of implementation of the myPTM device and relief of spasticity.


In this descriptive case series, 15 subjects, all with a simple continuous infusion mode with only baclofen, were tracked. We measured the number of patient activations of myPTM per day: mean was 3.62 (0.43), median = 3.62. Mean number of successful activations 17.5; unsuccessful 2.5; lockout attempts 1.5. Patient satisfaction was not measured regularly in all subjects.


We concluded that we need better outcome measurements for patient satisfaction with this device, and a way to measure satisfaction on more frequent basis than medical visits. Further, it would probably be more useful to quantify the improvement (the difference in pain and function before and after myPTM) of spasticity to delineate patient satisfaction as opposed to using anecdotal accounts from the patient. In addition, it would be ideal to study a larger number of patients in order to make claims representative of a wider population. However, we note that patients were able to activate device successfully majority of time, with few lockouts.